Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This is a phase II clinical study of the novel recombinant HPV 16/18 bivalent vaccine expressed in E. coli. The primary purpose of this study is to evaluate which dosage of the HPV vaccine can induce higher antibody and at the same time caused less adverse events. The secondary purpose of this study is to to evaluate the safety and immunopersistence of the study vaccine.
Epistemonikos ID: 9dc47599b9772016d032c15b53326e8c4d54f8b2
First added on: Mar 23, 2020